comparemela.com

Latest Breaking News On - Metastatic breast - Page 7 : comparemela.com

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Patrick-lin
David-young
Bret-shapiro
Processa-ngcs
Young
Pharmaceuticals-inc
Company-contact
Processa-pharmaceuticals-announces-expansion
Nasdaq
Processa-pharmaceuticals-inc
Processa-pharmaceuticals
Pharmaceuticals-announces-expansion

Endocrine Therapy Effective Subsequent Advanced Breast Cancer Treatment

Endocrine therapy, particularly when administered in combination with Verzenio (abemaciclib), is effective when compared with chemotherapy among patients with metastatic breast cancer who experienced disease progression on Ibrance (palbociclib), according to recently published research.

Peking
Beijing
China
San-antonio
Texas
United-states
Cdki-verzenio
Drug-administration
University-cancer-hospital
Key-laboratory-of-carcinogenesis
Translational-research-ministry-of-education
Key-laboratory

From Capecitabine to Tucatinib: Data Reveal New Treatment Options for Patients

Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

/PRNewswire/ Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of.

Germany
China
United-states
Italy
Asia-pacific
Fabio-piazzalunga
Wolfgang-janni
Department-of-obstetrics
Us-food-drug-administration
University-of-ulm
China-national-medical-products-administration
Menarini-group

Eisai's Commitment To Oncology Demonstrated By Clinical Data To Be Presented At ASCO Annual Meeting

LONDON, May 16 /PRNewswire/ Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the company s oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicag

London
City-of
United-kingdom
United-states
Chicago
Illinois
American
Mesylate
Haruo-naito
Prnewswire-eisai-europe-ltd
Ligand-pharmaceuticals
Eisai-co

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.